Tuberculosis drugs’ distribution and emergence of resistance in patient’s lung lesions: A mechanistic model and tool for regimen and dose optimization

PLoS Medicine

Volumn 16, Issue 4, 2019, Pages

  Strydom, Natasha ^a   Gupta, Sneha V ^a   Fox, William S ^a   Via, Laura E ^b   Bang, Hyeeun ^b   Lee, Myungsun ^c   Eum, Seokyong ^c   Shim, TaeSun ^d   Barry, Clifton E ^b   Zimmerman, Matthew ^e   Dartois, Véronique ^e   Savic, Radojka M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c International Tuberculosis Research Center   (South Korea)

^d Asan Medical Center   (South Korea)

^e PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFAZIMINE; ISONIAZID; KANAMYCIN; LINEZOLID; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; ATYPICAL MYCOBACTERIOSIS; CLINICAL ARTICLE; DRUG CLEARANCE; DRUG CONCENTRATION; DRUG PENETRATION; FEMALE; HUMAN; HUMAN TISSUE; LIMIT OF QUANTITATION; LUNG LESION; LUNG RESECTION; MALE; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; TUBERCULOSIS; VOLUME OF DISTRIBUTION; COMBINATION DRUG THERAPY; DECISION SUPPORT SYSTEM; DISEASE EXACERBATION; DOSE CALCULATION; DRUG ADMINISTRATION; DRUG EFFECT; LUNG; LUNG TUBERCULOSIS; METABOLISM; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; PATHOLOGY; RETROSPECTIVE STUDY; TISSUE DISTRIBUTION; TREATMENT FAILURE; YOUNG ADULT;

ADULT; ANTITUBERCULAR AGENTS; DECISION SUPPORT TECHNIQUES; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; ISONIAZID; KANAMYCIN; LINEZOLID; LUNG; MALE; MIDDLE AGED; PYRAZINAMIDE; RETROSPECTIVE STUDIES; RIFAMPIN; TISSUE DISTRIBUTION; TREATMENT FAILURE; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 85064194844     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1002773     Document Type: Article

References (45)

1. WHO | Report of the Technical Consultation on Advances in Clinical Trial Design for Development of New TB Treatments. WHO. World Health Organization; 2018; Available from: https://www.who.int/tb/publications/2018/clinical_trail_design_TB_treatments/en/ (Accessed December 21, 2018)
2. Jindani A, Harrison TS, Nunn AJ, Phillips PPJ, Churchyard GJ, Charalambous S, et al. High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis. N Engl J Med. Massachusetts Medical Society; 2014; 371: 1599–1608. https://doi.org/10.1056/NEJMoa1314210 PMID: 25337749
3. Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, et al. Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis. N Engl J Med. Massachusetts Medical Society; 2014; 371: 1577–1587. https://doi.org/10.1056/NEJMoa1407426 PMID: 25196020
4. Merle CS, Fielding K, Sow OB, Gninafon M, Lo MB, Mthiyane T, et al. A Four-Month Gatifloxacin-Con-taining Regimen for Treating Tuberculosis. N Engl J Med. Massachusetts Medical Society; 2014; 371: 1588–1598. https://doi.org/10.1056/NEJMoa1315817 PMID: 25337748
5. Barry CE, Boshoff HI, Dartois V, Dick T, Ehrt S, Flynn J, et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol. Nature Publishing Group; 2009; 7: 845. https://doi.org/10.1038/nrmicro2236 PMID: 19855401
6. Dartois V. The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells. Nat Rev Microbiol. Nature Publishing Group; 2014; 12: 159–67. https://doi.org/10.1038/nrmicro3200 PMID: 24487820
7. Prideaux B, Via LE, Zimmerman MD, Eum S, Sarathy J, O’Brien P, et al. The association between sterilizing activity and drug distribution into tuberculosis lesions. Nat Med. 2015; 21: 1223–7. https://doi.org/10.1038/nm.3937 PMID: 26343800
8. Pienaar E, Dartois V, Linderman JJ, Kirschner DE. In silico evaluation and exploration of antibiotic tuberculosis treatment regimens. BMC Syst Biol. 2015; 9: 79. https://doi.org/10.1186/s12918-015-0221-8 PMID: 26578235
9. Rifat D, Prideaux B, Savic RM, Urbanowski ME, Parsons TL, Luna B, et al. Pharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis and correlation with clinical trial data. Sci Transl Med. American Association for the Advancement of Science; 2018; 10: eaai7786. https://doi.org/10.1126/scitranslmed.aai7786 PMID: 29618565
10. Savic R, Weiner M, MacKenzie W, Engle M, Whitworth W, Johnson J, et al. Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials. Clin Pharmacol Ther. Wiley-Blackwell; 2017; 102: 321–331. https://doi.org/10.1002/cpt.634 PMID: 28124478
11. Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. CPT pharmacometrics Syst Pharmacol. 2013; 2: e38. https://doi.org/10.1038/psp.2013.14 PMID: 23887688
12. Savic RM, Jonker DM, Kerbusch T, Karlsson MO. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn. 2007; 34: 711–26. https://doi.org/10.1007/s10928-007-9066-0 PMID: 17653836
13. Kjellsson MC, Via LE, Goh A, Weiner D, Low KM, Kern S, et al. Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. Antimicrob Agents Chemother. 2012; 56: 446–457. https://doi.org/10.1128/AAC.05208-11 PMID: 21986820
14. Guiastrennec B, Hooker AC, Olofsson A, Ueckert S, Keizer R, Karlsson MO. xpose: Diagnostics for Pharmacometric Models [Internet]. 2017. Available from: https://cran.r-project.org/package=xpose (Accessed March 18, 2019)
15. Gumbo T. New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. Antimicrob Agents Chemother. American Society for Microbiology; 2010; 54: 1484–91. https://doi.org/10.1128/AAC.01474-09 PMID: 20086150
16. EUCAST. EUCAST. In: EUCAST [Internet]. 2015. Available from: http://www.eucast.org/ast_of_bacteria/ (Accessed March 18, 2019)
17. Lavielle M. mlxR: Simulation of Longitudinal Data [Internet]. 2017. Available from: https://cran.r-project.org/package=mlxR (Accessed March 18, 2019)
18. R Core Team. R: A Language and Environment for Statistical Computing [Internet]. Vienna, Austria; 2017. Available from: https://www.r-project.org/ (Accessed March 18, 2019)
19. RStudio Team. RStudio: Integrated Development Environment for R [Internet]. Boston, MA; 2015. Available from: http://www.rstudio.com/ (Accessed March 18, 2019)
20. Chang W, Cheng J, Allaire JJ, Xie Y, McPherson J. shiny: Web Application Framework for R [Internet]. 2017. Available from: https://cran.r-project.org/package=shiny (Accessed March 18, 2019)
21. Werely CJ, Donald PR, van Helden PD. NAT2 polymorphisms and their influence on the pharmacology and toxicity of isoniazid in TB patients. Per Med. Future Medicine Ltd London, UK; 2007; 4: 123–131. https://doi.org/10.2217/17410541.4.2.123 PMID: 29788627
22. Sarathy JP, Via LE, Weiner D, Blanc L, Boshoff H, Eugenin EA, et al. Extreme Drug Tolerance of Mycobacterium tuberculosis in Caseum. Antimicrob Agents Chemother. American Society for Microbiology; 2018; 62: e02266–17. https://doi.org/10.1128/AAC.02266-17 PMID: 29203492
23. Lanoix J-P, Ioerger T, Ormond A, Kaya F, Sacchettini J, Dartois V, et al. Selective Inactivity of Pyrazinamide against Tuberculosis in C3HeB/FeJ Mice Is Best Explained by Neutral pH of Caseum. Antimicrob Agents Chemother. American Society for Microbiology (ASM); 2016; 60: 735–43. https://doi.org/10.1128/AAC.01370-15 PMID: 26574016
24. Irwin SM, Gruppo V, Brooks E, Gilliland J, Scherman M, Reichlen MJ, et al. Limited Activity of Clofazimine as a Single Drug in a Mouse Model of Tuberculosis Exhibiting Caseous Necrotic Granulomas. Antimicrob Agents Chemother. 2014; 58: 4026–4034. https://doi.org/10.1128/AAC.02565-14 PMID: 24798275
25. Jayaram R, Shandil RK, Gaonkar S, Kaur P, Suresh BL, Mahesh BN, et al. Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother. 2004; 48: 2951–2957. https://doi.org/10.1128/AAC.48.8.2951-2957.2004 PMID: 15273105
26. Lakshminarayana SB, Huat TB, Ho PC, Manjunatha UH, Dartois V, Dick T, et al. Comprehensive physi-cochemical, pharmacokinetic and activity profiling of anti-TB agents. J Antimicrob Chemother. 2015; 70: 857–67. https://doi.org/10.1093/jac/dku457 PMID: 25587994
27. Kashuba AD, Nafziger AN, Drusano GL, Bertino JS. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother. American Society for Microbiology; 1999; 43: 623–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10049277 (Accessed March 18, 2019) PMID: 10049277
28. Boak LM, Rayner CR, Grayson ML, Paterson DL, Spelman D, Khumra S, et al. Clinical Population Pharmacokinetics and Toxicodynamics of Linezolid. Antimicrob Agents Chemother. 2014; 58: 2334–2343. https://doi.org/10.1128/AAC.01885-13 PMID: 24514086
29. Sarathy JP, Via LE, Weiner D, Blanc L, Boshoff H, Eugenin EA, et al. Extreme Drug Tolerance of Mycobacterium tuberculosis in Caseum. Antimicrob Agents Chemother. American Society for Microbiology; 2018; 62: e02266–17. https://doi.org/10.1128/AAC.02266-17 PMID: 29203492
30. Heinrichs MT, Vashakidze S, Nikolaishvili K, Sabulua I, Tukvadze N, Bablishvili N, et al. Moxifloxacin target site concentrations in patients with pulmonary TB utilizing microdialysis: a clinical pharmacokinetic study. J Antimicrob Chemother. 2018; 73: 477–483. https://doi.org/10.1093/jac/ dkx421 PMID: 29186509
31. Jindani A, Harrison TS, Nunn AJ, Phillips PPJ, Churchyard GJ, Charalambous S, et al. High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis. N Engl J Med. Massachusetts Medical Society; 2014; 371: 1599–1608. https://doi.org/10.1056/NEJMoa1314210 PMID: 25337749
32. Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, et al. Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis. N Engl J Med. Massachusetts Medical Society; 2014; 371: 1577–1587. https://doi.org/10.1056/NEJMoa1407426 PMID: 25196020
33. Drusano GL, Sgambati N, Eichas A, Brown DL, Kulawy R, Louie A. The Combination of Rifampin plus Moxifloxacin Is Synergistic for Suppression of Resistance but Antagonistic for Cell Kill of Mycobacterium tuberculosis as Determined in a Hollow-Fiber Infection Model. MBio. 2010; 1: e00139-10–e00139-10. https://doi.org/10.1128/mBio.00139-10 PMID: 20802826
34. Dooley K, Flexner C, Hackman J, Peloquin CA, Nuermberger E, Chaisson RE, et al. Repeated Administration of High-Dose Intermittent Rifapentine Reduces Rifapentine and Moxifloxacin Plasma Concentrations. Antimicrob Agents Chemother. 2008; 52: 4037–4042. https://doi.org/10.1128/AAC.00554-08PMID: 18765687
35. Reuter A, Tisile P, von Delft D, Cox H, Cox V, Ditiu L, et al. The devil we know: is the use of injectable agents for the treatment of MDR-TB justified? Int J Tuberc Lung Dis. 2017; 21: 1114–1126. https://doi.org/10.5588/ijtld.17.0468 PMID: 29037291
36. WHO | Rapid Communication: Key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB). WHO. World Health Organization; 2018; Available from: https://www.who.int/tb/publications/2018/rapid_communications_MDR/en/ (Accessed March 18, 2019)
37. Conradie F, Diacon AH, Everitt D, Mendel CM, van Niekerk C, Howell P, et al. Sustained high rate of successful treatment outcomes: interim results of 75 patients in the Nix-TB clinical study of pretomanid, bedaquiline and linezolid. Oral presentation at 49th World Conference on lung health of the International Union against tuberculosis and lung disease (The Union) October 25, 2018, The Hague, The Netherlands. The Hague; 2018. p. S69. Available from: https://www.abstractserver.com/TheUnion2018/TheUnion2018_Abstracts_Web.pdf (Accessed March 18, 2019)
38. Colangeli R, Jedrey H, Kim S, Connell R, Ma S, Chippada Venkata UD, et al. Bacterial Factors That Predict Relapse after Tuberculosis Therapy. N Engl J Med. 2018; 379: 823–833. https://doi.org/10.1056/NEJMoa1715849 PMID: 30157391
39. Imperial MZ, Nahid P, Phillips PPJ, Davies GR, Fielding K, Hanna D, et al. A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. Nat Med. Nature Publishing Group; 2018; 24: 1708–1715. https://doi.org/10.1038/s41591-018-0224-2 PMID: 30397355
40. Huang Q, Yin Y, Kuai S, Yan Y, Liu J, Zhang Y, et al. The value of initial cavitation to predict re-treatment with pulmonary tuberculosis. Eur J Med Res. BioMed Central; 2016; 21: 20. https://doi.org/10.1186/ s40001-016-0214-0 PMID: 27154410
41. Kaplan G, Post FA, Moreira AL, Wainwright H, Kreiswirth BN, Tanverdi M, et al. Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect Immun. 2003; 71: 7099–108. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14638800 (Accessed March 18, 2019) https://doi.org/10.1128/IAI.71.12.7099-7108.2003 PMID: 14638800
42. Kempker RR, Rabin AS, Nikolaishvili K, Kalandadze I, Gogishvili S, Blumberg HM, et al. Additional drug resistance in Mycobacterium tuberculosis isolates from resected cavities among patients with multidrug-resistant or extensively drug-resistant pulmonary tuberculosis. Clin Infect Dis. 2012; 54: e51–4. https://doi.org/10.1093/cid/cir904 PMID: 22198790
43. Blanc L, Daudelin IB, Podell BK, Chen P-Y, Zimmerman M, Martinot AJ, et al. High-resolution mapping of fluoroquinolones in TB rabbit lesions reveals specific distribution in immune cell types. Elife. 2018; 7. https://doi.org/10.7554/eLife.41115 PMID: 30427309
44. Irwin SM, Prideaux B, Lyon ER, Zimmerman MD, Brooks EJ, Schrupp CA, et al. Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in Mycobacterium tuberculosis Infected C3HeB/FeJ Mice. ACS Infect Dis. 2016; 2: 251–267. https://doi.org/10.1021/acsinfecdis.5b00127 PMID: 27227164
45. Sarathy JP, Zuccotto F, Hsinpin H, Sandberg L, Via LE, Marriner GA, et al. Prediction of Drug Penetration in Tuberculosis Lesions. ACS Infect Dis. NIH Public Access; 2016; 2: 552–63. https://doi.org/10.1021/acsinfecdis.6b00051 PMID: 27626295